| 3.49 0.05 (1.45%) | 12-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.15 |
1-year : | 17.19 |
| Resists | First : | 10.4 |
Second : | 14.72 |
| Pivot price | 13.12 |
|||
| Supports | First : | 3.42 |
Second : | 2.84 |
| MAs | MA(5) : | 11.47 |
MA(20) : | 13.26 |
| MA(100) : | 14.13 |
MA(250) : | 13.82  |
|
| MACD | MACD : | -0.9 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 25.4 |
D(3) : | 30.1 |
| RSI | RSI(14): 16 |
|||
| 52-week | High : | 18.79 | Low : | 2.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NLTX ] has closed below the lower bollinger band by 42.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NLTX ] is to continue within current trading range. It is unclear right now based on current values. 266.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.59 - 3.61 | 3.61 - 3.62 |
| Low: | 3.38 - 3.4 | 3.4 - 3.41 |
| Close: | 3.46 - 3.49 | 3.49 - 3.52 |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Tue, 16 Apr 2024
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down - Yahoo Lifestyle UK
Thu, 14 Dec 2023
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split - GlobeNewswire
Tue, 26 Sep 2023
Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7% - Dhaka Tribune
Fri, 22 Sep 2023
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split - Yahoo Finance
Thu, 27 Jul 2023
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc - Yahoo Finance
Tue, 18 Jul 2023
Fenwick Represents Neoleukin in Merger Agreement with… | Fenwick - Fenwick & West LLP
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -12.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|